Nihanthy D. Sreenath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nihanthy D. Sreenath has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Akhil Santhosh
Department of Medical Oncology, MVR Cancer Centre and Research Institute, Calicut, Kerala, India
3 shared publications - Naveen Kumar Kushwaha
Department of Thoracic Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
3 shared publications Rajath Govind
Consultant (Medicine and Medical Oncology) Army Hospital (R&R) New Delhi India
3 shared publications- Sameer Rastogi
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
2 shared publications - Adarsh Barwad
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Akash Singh
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
1 shared publication
Latest Publications
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500361
Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries
PURPOSE: In low- and middle-income countries (LMICs), access to traditional oncology education through conferences, journals, and in-person mentorship is often restricted. Social media has emerged as a potential tool to bridge this gap; however, its educational and clinical influence on oncology professionals remains underexplored. METHODS: We conducted a cross-sectional, anonymized, web-based survey of 202 oncology professionals from 13 countries. A 30-item questionnaire was used for the survey. Data were analyzed using descriptive statistics and chi-square tests. RESULTS: Among the respondents, 93% practiced in India, with 61% identifying Twitter (X) as their primary oncology information source. Daily engagement was reported by 53% of the respondents. The most valued benefits were early access to emerging research (30%) and trial updates (29%). Social media discussions atleast moderately influenced clinical decision making in 75% of respondents, with 29% reporting a substantial impact, which was a subjective assessment of the participants. Virtual tumor boards engaged 58% of the participants and prompted practice changes in 21%. Sixty-eight percent credited social media, with expanding their professional networks, and 25% initiated research collaborations through these platforms. Structured digital literacy training and tools, such as automated fact-checking and professional credential verification, were supported by over two thirds of the participants. CONCLUSION: Social media has become an essential educational and collaborative platform for oncology professionals, particularly in LMICs. By enabling timely access to research and supporting peer learning, it complements the traditional modes of oncology education. The formal integration of digital literacy training and content-verification mechanisms may enhance its safe and equitable use.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500361
Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries
PURPOSE: In low- and middle-income countries (LMICs), access to traditional oncology education through conferences, journals, and in-person mentorship is often restricted. Social media has emerged as a potential tool to bridge this gap; however, its educational and clinical influence on oncology professionals remains underexplored. METHODS: We conducted a cross-sectional, anonymized, web-based survey of 202 oncology professionals from 13 countries. A 30-item questionnaire was used for the survey. Data were analyzed using descriptive statistics and chi-square tests. RESULTS: Among the respondents, 93% practiced in India, with 61% identifying Twitter (X) as their primary oncology information source. Daily engagement was reported by 53% of the respondents. The most valued benefits were early access to emerging research (30%) and trial updates (29%). Social media discussions atleast moderately influenced clinical decision making in 75% of respondents, with 29% reporting a substantial impact, which was a subjective assessment of the participants. Virtual tumor boards engaged 58% of the participants and prompted practice changes in 21%. Sixty-eight percent credited social media, with expanding their professional networks, and 25% initiated research collaborations through these platforms. Structured digital literacy training and tools, such as automated fact-checking and professional credential verification, were supported by over two thirds of the participants. CONCLUSION: Social media has become an essential educational and collaborative platform for oncology professionals, particularly in LMICs. By enabling timely access to research and supporting peer learning, it complements the traditional modes of oncology education. The formal integration of digital literacy training and content-verification mechanisms may enhance its safe and equitable use.
- Open Access
- 4 May 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 47 (05) , 418-419
KEYNOTE-689 and the Perioperative Paradigm: A Critical Appraisal of Design-Driven Success
- 4 May 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 47 (05) , 418-419
Open AccessKEYNOTE-689 and the Perioperative Paradigm: A Critical Appraisal of Design-Driven Success
- Open Access
- 18 March 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 47 (03) , 230-231
Where Science Pauses, and the Soul Begins: Pastries, Prognosis, and the Poetry of Passing
There is a hush between naming a disease and letting someone go—a space too quiet for science, too sacred for metrics. In that flickering gap where knowledge reaches its limit, and love begins to listen; we often find ourselves. Not in clinical guidelines or Kaplan–Meier curves, but in the tremble of a hand, the silence between sobs, the dreams that unravel without fanfare. That is where we met Maya. She came to us on a monsoon evening. The sky was dark, and the air hung heavy with rain and something else. Something unnamed. Maya was just thirty. Metastatic breast cancer had already made a home of her body, uninvited and unrelenting. Her prognosis was written in cold lines and percentages, but she arrived with warmth that defied them. She wore bright scarves; crimson, marigold, turquoise—like little rebellions tied around her head. “If I must lose my hair,” she smiled, “let me at least wear a little sunshine.” Maya had once dreamt of becoming a baker. Not a celebrity chef, not a patisserie connoisseur just someone who could open a little bakery tucked into a quiet street where the smell of cardamom buns and mango tarts would spill into the morning air. She believed in the alchemy of sugar and sorrow. “There's something holy,” she once said, “In the way heat and sweetness can soften grief.” For Maya, baking was sacred. Memory kneaded into dough. Love poured into molds. Healing—slow, deliberate, one slice at a time. She had been saving for pastry school in Paris. But cancer is ravenous, it devours more than just the body. It takes not just health, but hope. Not just time, but timelines. Her savings disappeared into travel, consultations, scans. The dream stayed folded inside a drawer she would never reopen. We rarely spoke in numbers. Instead, we talked of quieter things—poems, pastries, the smell of summers past, and the mango tree that grew wild behind her childhood home. Her questions were never about dying. They were about time: “Will I be well enough to bake my brother's birthday cake?” “Do you think I'll still be here when the jacarandas bloom?” As her body thinned, her spirit expanded. She grew more luminous as she grew weaker, fiercely tender even as her strength drained away. She didn't fight the cancer; she made room for it. Not with surrender, but with grace. With eyes wide open and an aching kind of joy. She wove life around it. Fierce in fragility. And then, one day, she broke. She had just returned from a draining chemo session, hands shaking from fatigue. Her voice was small, almost not there. “I've never said this before,” she whispered, “but I lost both my parents in a car accident; years ago. I raised my younger brother after that. He's just twenty now. He doesn't show it, but I know he's scared. He's all I have. I'm all he has. What happens to him… when I go?” And in that moment, the room felt too small for the weight of her grief. It was the kind of pain no medication could touch, grief not just for her life, but for the life she wouldn't get to protect. Her fear wasn't death but it was abandonment. Of a boy she had mothered in her own mourning. Of a dream she had carried through too much loss already. Even as her body failed her, she held on to care, to kinship, to crumbs of love she kept leaving behind, hoping they'd be enough to lead her brother forward. Between chemo cycles, she would sometimes bring us peach muffins, lemon madeleines—baked in the windows of strength between nausea and fatigue. Her hands had started to tremble. Her fingertips bore the bruises of countless intravenous lines. But still, she stirred, she poured, and she baked. Each bite was defiance. Each dessert a quiet, quivering stand against despair. “I may never own that bakery,” she once whispered, “but I've baked more love into the world than most get to in a lifetime.” And it was true. There was such aching in her acceptance. Not resignation but a quiet, sacred grace. A recognition that life had not been fair, but she could still make something beautiful out of what remained. A kind of luminous surrender that isn't about giving up, but about giving in to what is, and still choosing beauty. In Maya, we saw a kind of courage that doesn't roar nor makes headlines. It stirs quietly in a steel bowl. It rises slowly in a warm oven. It shows up in soft-spoken sisters who shoulder entire families. In women who do not get the future they deserve, but still insist on loving what little is left. Her story is not rare. It echoes across clinics and countries; where dreams are interrupted not just by disease but by disparities. Where women like Maya don't just fight cancer; they fight for dignity, for access, and for the right to dream beyond diagnosis. And as the 21st century unfolds with artificial intelligence and molecular magic, with targeted therapies and genomic marvels; we must not forget the trembling, tender heart of medicine. The heart of healing lies not just in intervention, but in presence. To hold a hand. To wait in silence. To ask, not only “What hurts?” but “What matters?” To honor not just the science of cure, but the art of care. Maya left on a gray, rain-washed afternoon, as quietly as she had lived. Months after Maya was gone, her younger brother came to visit us. He arrived quietly and shoulders curved with a grief too heavy for someone so young. He had been just a child; barely six years old when they lost their parents. Too young to remember the exact texture of his mother's voice, but old enough to remember how Maya stepped in, arms barely grown, and became everything: mother, sister, shelter, and light. “I don't remember Amma much,” he whispered, “but I remember Maya, flour on her face, kneading dough with all the love she didn't know how to say.” What we hadn't known was...
- 18 March 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 47 (03) , 230-231
Open AccessWhere Science Pauses, and the Soul Begins: Pastries, Prognosis, and the Poetry of Passing
There is a hush between naming a disease and letting someone go—a space too quiet for science, too sacred for metrics. In that flickering gap where knowledge reaches its limit, and love begins to listen; we often find ourselves. Not in clinical guidelines or Kaplan–Meier curves, but in the tremble of a hand, the silence between sobs, the dreams that unravel without fanfare. That is where we met Maya. She came to us on a monsoon evening. The sky was dark, and the air hung heavy with rain and something else. Something unnamed. Maya was just thirty. Metastatic breast cancer had already made a home of her body, uninvited and unrelenting. Her prognosis was written in cold lines and percentages, but she arrived with warmth that defied them. She wore bright scarves; crimson, marigold, turquoise—like little rebellions tied around her head. “If I must lose my hair,” she smiled, “let me at least wear a little sunshine.” Maya had once dreamt of becoming a baker. Not a celebrity chef, not a patisserie connoisseur just someone who could open a little bakery tucked into a quiet street where the smell of cardamom buns and mango tarts would spill into the morning air. She believed in the alchemy of sugar and sorrow. “There's something holy,” she once said, “In the way heat and sweetness can soften grief.” For Maya, baking was sacred. Memory kneaded into dough. Love poured into molds. Healing—slow, deliberate, one slice at a time. She had been saving for pastry school in Paris. But cancer is ravenous, it devours more than just the body. It takes not just health, but hope. Not just time, but timelines. Her savings disappeared into travel, consultations, scans. The dream stayed folded inside a drawer she would never reopen. We rarely spoke in numbers. Instead, we talked of quieter things—poems, pastries, the smell of summers past, and the mango tree that grew wild behind her childhood home. Her questions were never about dying. They were about time: “Will I be well enough to bake my brother's birthday cake?” “Do you think I'll still be here when the jacarandas bloom?” As her body thinned, her spirit expanded. She grew more luminous as she grew weaker, fiercely tender even as her strength drained away. She didn't fight the cancer; she made room for it. Not with surrender, but with grace. With eyes wide open and an aching kind of joy. She wove life around it. Fierce in fragility. And then, one day, she broke. She had just returned from a draining chemo session, hands shaking from fatigue. Her voice was small, almost not there. “I've never said this before,” she whispered, “but I lost both my parents in a car accident; years ago. I raised my younger brother after that. He's just twenty now. He doesn't show it, but I know he's scared. He's all I have. I'm all he has. What happens to him… when I go?” And in that moment, the room felt too small for the weight of her grief. It was the kind of pain no medication could touch, grief not just for her life, but for the life she wouldn't get to protect. Her fear wasn't death but it was abandonment. Of a boy she had mothered in her own mourning. Of a dream she had carried through too much loss already. Even as her body failed her, she held on to care, to kinship, to crumbs of love she kept leaving behind, hoping they'd be enough to lead her brother forward. Between chemo cycles, she would sometimes bring us peach muffins, lemon madeleines—baked in the windows of strength between nausea and fatigue. Her hands had started to tremble. Her fingertips bore the bruises of countless intravenous lines. But still, she stirred, she poured, and she baked. Each bite was defiance. Each dessert a quiet, quivering stand against despair. “I may never own that bakery,” she once whispered, “but I've baked more love into the world than most get to in a lifetime.” And it was true. There was such aching in her acceptance. Not resignation but a quiet, sacred grace. A recognition that life had not been fair, but she could still make something beautiful out of what remained. A kind of luminous surrender that isn't about giving up, but about giving in to what is, and still choosing beauty. In Maya, we saw a kind of courage that doesn't roar nor makes headlines. It stirs quietly in a steel bowl. It rises slowly in a warm oven. It shows up in soft-spoken sisters who shoulder entire families. In women who do not get the future they deserve, but still insist on loving what little is left. Her story is not rare. It echoes across clinics and countries; where dreams are interrupted not just by disease but by disparities. Where women like Maya don't just fight cancer; they fight for dignity, for access, and for the right to dream beyond diagnosis. And as the 21st century unfolds with artificial intelligence and molecular magic, with targeted therapies and genomic marvels; we must not forget the trembling, tender heart of medicine. The heart of healing lies not just in intervention, but in presence. To hold a hand. To wait in silence. To ask, not only “What hurts?” but “What matters?” To honor not just the science of cure, but the art of care. Maya left on a gray, rain-washed afternoon, as quietly as she had lived. Months after Maya was gone, her younger brother came to visit us. He arrived quietly and shoulders curved with a grief too heavy for someone so young. He had been just a child; barely six years old when they lost their parents. Too young to remember the exact texture of his mother's voice, but old enough to remember how Maya stepped in, arms barely grown, and became everything: mother, sister, shelter, and light. “I don't remember Amma much,” he whispered, “but I remember Maya, flour on her face, kneading dough with all the love she didn't know how to say.” What we hadn't known was...
- Top Cited Papers
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500440
Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow
PURPOSE: Sarcomas exhibit clinicopathologic heterogeneity, leading to diagnostic and therapeutic uncertainty. This study assesses the clinical value of integrating targeted RNA-based next-generation sequencing (NGS) into a multidisciplinary sarcoma workflow to improve diagnosis, enable comprehensive molecular characterization, and inform personalized treatment strategies. METHODS: In this prospective single-center study, 68 patients with suspected or confirmed soft tissue sarcoma underwent RNA-based NGS using a 138-gene fusion panel, integrated within a multidisciplinary sarcoma framework. Genomic findings integrated with histopathology and immunohistochemistry for diagnostic reclassification and treatment changes. RESULTS: Of 70 patients advised RNA-based NGS, 68 (97.1%) were evaluable (median age, 38.5 years). Soft tissue sarcomas predominated (77.1%), with 67.1% presenting with advanced disease. Initial histology included 17 round cell sarcomas (RC), 19 undifferentiated sarcomas (US), and 34 other subtypes. Among evaluable RC cases (n = 16), NGS identified diagnostic fusions in 87.5%, enabling reclassification in 68.7% and treatment change in 18.7%. In US, fusions were detected in 21.1%, all reclassified, with treatment altered in 75%. In other subtypes, fusions were found in 48.4%, enabling reclassification in 39.3% and treatment impact in 21.2%. Nondiagnostic mutations (eg, TP53 , SLX4 , NF1 ) were observed in 47.4% of US and 18.2% of other subtypes. Potentially actionable variants ( KIT , PIK3CA ) were seen in 5.8%. Overall, RNA-NGS was clinically informative in 50%, refined diagnosis in 41.1%, and influenced treatment in 26.4% of patients. CONCLUSION: To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500440
Top Cited PapersClinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow
PURPOSE: Sarcomas exhibit clinicopathologic heterogeneity, leading to diagnostic and therapeutic uncertainty. This study assesses the clinical value of integrating targeted RNA-based next-generation sequencing (NGS) into a multidisciplinary sarcoma workflow to improve diagnosis, enable comprehensive molecular characterization, and inform personalized treatment strategies. METHODS: In this prospective single-center study, 68 patients with suspected or confirmed soft tissue sarcoma underwent RNA-based NGS using a 138-gene fusion panel, integrated within a multidisciplinary sarcoma framework. Genomic findings integrated with histopathology and immunohistochemistry for diagnostic reclassification and treatment changes. RESULTS: Of 70 patients advised RNA-based NGS, 68 (97.1%) were evaluable (median age, 38.5 years). Soft tissue sarcomas predominated (77.1%), with 67.1% presenting with advanced disease. Initial histology included 17 round cell sarcomas (RC), 19 undifferentiated sarcomas (US), and 34 other subtypes. Among evaluable RC cases (n = 16), NGS identified diagnostic fusions in 87.5%, enabling reclassification in 68.7% and treatment change in 18.7%. In US, fusions were detected in 21.1%, all reclassified, with treatment altered in 75%. In other subtypes, fusions were found in 48.4%, enabling reclassification in 39.3% and treatment impact in 21.2%. Nondiagnostic mutations (eg, TP53 , SLX4 , NF1 ) were observed in 47.4% of US and 18.2% of other subtypes. Potentially actionable variants ( KIT , PIK3CA ) were seen in 5.8%. Overall, RNA-NGS was clinically informative in 50%, refined diagnosis in 41.1%, and influenced treatment in 26.4% of patients. CONCLUSION: To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500619
Bold Brushstrokes, Bravery, and the Bat-Fan: The Girl Who Laughed in Color
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500619
Bold Brushstrokes, Bravery, and the Bat-Fan: The Girl Who Laughed in Color
- 2 December 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1)
Gastrointestinal Stromal Tumours: Epitome of Variability
- 2 December 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1)
Gastrointestinal Stromal Tumours: Epitome of Variability
- Open Access
- 24 November 2025
- Published by Wiley in Aging and Cancer
- Vol. 7 (1) , 3-11
Enhancing Oncological Care for India's Aging Population: Addressing the Complex Needs of Older Adults With Cancer
Cancer in older adults is a growing public health concern in India, with approximately 50% of all new cancer cases occurring in individuals aged 60 years and above, according to recent estimates from the Indian Council of Medical Research (ICMR). Older adults often present with a distinct set of medical, psychological, and social vulnerabilities that necessitate tailored approaches to cancer management. The increasing prevalence of solid malignancies among older adults presents substantial challenges for an already overburdened healthcare system. However, oncology care in India lacks a geriatric‐oriented approach, resulting in gaps in both accessibility and quality for older populations. This review provides a detailed exploration of the multidimensional issues of treating older adults with malignancies in India, examining current deficiencies in healthcare delivery, socio‐economic constraints, and potential avenues for enhancing care quality through multidisciplinary collaboration, palliative care integration, and policy reform. The recommendations herein advocate for a model of care that emphasizes holistic support, ensuring dignity, accessibility, and quality outcomes for older adults with cancer in India.
- 24 November 2025
- Published by Wiley in Aging and Cancer
- Vol. 7 (1) , 3-11
Open AccessEnhancing Oncological Care for India's Aging Population: Addressing the Complex Needs of Older Adults With Cancer
Cancer in older adults is a growing public health concern in India, with approximately 50% of all new cancer cases occurring in individuals aged 60 years and above, according to recent estimates from the Indian Council of Medical Research (ICMR). Older adults often present with a distinct set of medical, psychological, and social vulnerabilities that necessitate tailored approaches to cancer management. The increasing prevalence of solid malignancies among older adults presents substantial challenges for an already overburdened healthcare system. However, oncology care in India lacks a geriatric‐oriented approach, resulting in gaps in both accessibility and quality for older populations. This review provides a detailed exploration of the multidimensional issues of treating older adults with malignancies in India, examining current deficiencies in healthcare delivery, socio‐economic constraints, and potential avenues for enhancing care quality through multidisciplinary collaboration, palliative care integration, and policy reform. The recommendations herein advocate for a model of care that emphasizes holistic support, ensuring dignity, accessibility, and quality outcomes for older adults with cancer in India.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (9) , 1218-1220
From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (9) , 1218-1220
From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma
- Open Access
- 18 August 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients. This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world performance of Palbociclib and Ribociclib. Patients were treated with either Palbociclib or Ribociclib in combination with standard endocrine therapy. Among the 60 patients, the median PFS was 39.40 months for the Palbociclib group and 42.93 months for the Ribociclib group (p = 0.26), indicating no statistically significant difference. The median OS was 41.98 months in the Palbociclib group and 45.51 months in the Ribociclib group (p = 0.15), with Ribociclib showing a slight but non-significant survival advantage. The most common adverse event was neutropenia, which occurred in 26% of patients receiving Palbociclib and 23% of patients on Ribociclib. Deranged liver function tests (LFTs) and fatigue were also reported in both groups. Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents.
- 18 August 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Open AccessA comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients. This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world performance of Palbociclib and Ribociclib. Patients were treated with either Palbociclib or Ribociclib in combination with standard endocrine therapy. Among the 60 patients, the median PFS was 39.40 months for the Palbociclib group and 42.93 months for the Ribociclib group (p = 0.26), indicating no statistically significant difference. The median OS was 41.98 months in the Palbociclib group and 45.51 months in the Ribociclib group (p = 0.15), with Ribociclib showing a slight but non-significant survival advantage. The most common adverse event was neutropenia, which occurred in 26% of patients receiving Palbociclib and 23% of patients on Ribociclib. Deranged liver function tests (LFTs) and fatigue were also reported in both groups. Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500239
Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500239
Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return